[Real-life study with pharmaceutical cannabidiol in refractory epilepsy]

Area of Science:

• Neurology
• Pharmacology

Context:

• Drug-resistant epilepsy (DRE) presents significant treatment challenges.
• Pharmaceutical-grade cannabidiol (CBD) is an established alternative therapy for DRE.
• A hospital implemented a non-medical change (NMC) involving the substitution of one commercial CBD product for another.

Purpose:

• To evaluate the clinical outcomes of switching commercial pharmaceutical-grade CBD products in DRE patients.
• To assess the efficacy and safety of a new CBD product for DRE treatment.

Summary:

• A retrospective cohort study included 19 DRE patients (12 switching, 7 new users).
• Outcomes measured included seizure frequency, Patient Global Impression of Change (PGIC), and adverse events.
• 44% of patients experienced reduced seizure frequency, and 22% reported improvement on the PGIC scale. Adverse events were mild and transient.

Impact:

• The new commercial pharmaceutical-grade CBD product is a safe and effective option for DRE patients.
• This product can be used for both switching existing treatments and initiating new therapy in DRE management.
• Patient-reported outcomes indicate stability or improvement in their condition.